1. Hong Kong Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
China Resources Pharmaceutical Group Limited

China Resources Pharmaceutical Group Limited

3320.HK
China Resources Pharmaceutical Group LimitedHK flagHong Kong Stock Exchange
4.76
HKD
+0.05
- -
29.90BMarket Cap
China Resources Pharmaceutical Group Limited
3320.HK
(Hong Kong Stock Exchange)

Recent

price

4.76

P/E

ratio

- -

div

yld

- -

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
FRC
14.81
17.59
19.88
28.56
22.94
26.51
29.23
26.88
30.81
34.73
38.95
41.01
- -
Revenue per Share
0.33
0.34
0.39
0.51
0.46
0.56
0.47
0.44
0.49
0.56
0.61
0.53
- -
Basic EPS, GAAP
0.14
0.13
0.49
0.42
0.38
0.88
0.87
0.8
1.26
1.29
1.98
2.28
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
0.08
0.1
0.12
0.09
0.1
0.13
0.14
0.24
- -
Dividend per Share
0.59
1.62
1.69
4.97
3.62
3.81
3.89
3.65
3.92
3.92
3.92
8.93
- -
Book Value per Share
1.49
2.01
2.26
5.61
4.67
4.62
6.31
6.97
7.95
8.37
10.1
10.69
- -
Tangible Book Value per Share
6,173
6,173
6,173
4,912
6,285
6,285
6,285
6,283
6,283
6,283
6,283
6,283
- -
Basic Weighted Avg Shares
91,386
108,551
122,733
140,314
144,169
166,596
183,669
168,907
193,564
218,183
244,704
257,673
269,574
Sales/Revenue/Turnover
7.49
6.85
6.96
6.62
6.66
7.01
5.08
5.65
5.3
5.66
5.13
5.15
5.21
Operating Margin (%)
934
1,082
1,127
1,141
1,308
1,420
2,124
2,060
2,307
2,558
3,164
3,357
4,082
Depreciation Expense
2,063
2,116
2,387
2,526
2,910
3,493
2,952
2,779
3,081
3,500
3,854
3,351
4,045
Net Income, GAAP
21.1
20.67
24.45
25.79
19.99
17.54
23.22
24.76
20.94
20.37
21.31
23.12
18.17
Effective Tax Rate (%)
2.26
1.95
1.94
1.8
2.02
2.1
1.61
1.65
1.59
1.6
1.58
1.3
1.5
Profit Margin (%)
7,736
15,037
13,928
20,431
17,936
20,997
23,600
20,638
28,851
30,489
44,335
53,624
59,498
Working Capital
8,638
13,524
10,788
5,717
2,878
8,914
9,771
2,666
6,633
9,812
15,937
23,632
22,077
LT Debt
25,512
29,707
33,366
48,622
52,758
53,107
62,508
67,445
77,659
80,557
92,975
98,087
117,456
Total Equity
- -
10.71
10.31
10.03
9.81
10.49
7.2
7.03
7.14
7.89
7.04
6.37
6.48
Return on Invested Capital (%)
- -
2.58
1.79
1.52
2.36
3.1
4.45
3.49
2.56
2.13
1.5
0.03
0.05
Return on Capital (%)
- -
31.13
23.38
14.5
12.34
14.96
12.2
11.72
12.95
14.21
15.65
8.3
7.01
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Working Capital

FRC

•

in mil. unless spec.
No data availableFinancial data will appear here once available

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
14%
11.91%
19.75%
Free Cash Flow
25.32%
29.24%
18.11%
Net Income, GAAP
6.2%
8.45%
20.73%
Sales/Revenue/Turnover
8.42%
9.88%
4.62%
Total Cash Common Dividend
- -
13.5%
-47.68%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
244,704
2024
- -
- -
- -
- -
257,673
2025
- -
- -
- -
- -
269,574

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.61
2024
- -
- -
- -
- -
0.53
2025
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
0.14
2024
- -
- -
- -
- -
0.24
2025
- -
- -
- -
- -
- -
Similar Companies
Sumitomo Pharma Co., Ltd. (SMDPY)
Lobe Sciences Ltd. (LOBEF)
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS)
FutureChem Co.,Ltd (220100.KQ)
Icanic Brands Company Inc. (ICAN.CN)
China Shineway Pharmaceutical Group Limited (CSWYF)
Business
China Resources Pharmaceutical Group Limited (Ticker: 3320.HK) is a leading pharmaceutical conglomerate headquartered in Hong Kong, founded in 1998. It operates primarily in the pharmaceutical manufacturing and distribution industry, offering a comprehensive portfolio of products and services that includes active pharmaceutical ingredients; finished dosage forms such as tablets, capsules, and injectables; Chinese patent medicines; health supplements; and medical devices. The company also engages in pharmaceutical distribution, retail pharmacy chains, and healthcare services across Mainland China and other regions. The company maintains extensive operations in Mainland China, with a strong presence in both the upstream pharmaceutical manufacturing sector and the downstream pharmaceutical distribution and retail markets. China Resources Pharmaceutical caters to a broad customer base including hospitals, pharmacies, healthcare institutions, and consumers seeking traditional and modern pharmaceutical products. In recent years, China Resources Pharmaceutical has pursued strategic expansions and business enhancements, including partnerships to strengthen its pharmaceutical supply chain, investments in biotechnology innovation, and the launch of new healthcare products. Notably, it has expanded its capabilities in innovative drug development as well as increasing its footprint in pharmaceutical distribution networks. The company continues to leverage its integrated business model to enhance operational efficiency and market competitiveness within China’s evolving healthcare landscape. China Resources Pharmaceutical Group Limited is a subsidiary under China Resources Holdings Company, benefiting from the parent group's broad industrial and financial support. The company remains committed to innovation-driven growth and enhancing healthcare accessibility through its diversified product lines and service offerings.